HomeAbbott

Abbott

Sanquin Selects Abbott’s “Alinity s” Solution for Blood and Plasma Screening

Sanquin and Abbott announced today that they signed a multiple-year contract for the supply of primary serological equipment and consumables, including Abbott's Alinity™ s system, for blood and plasma screening. This agreement extends Abbott and Sanquin’s long-standing...

Abbott Initiates Landmark GUIDE-HF Trial Using the CardioMEMS™ HF System

Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New...

Abbott Secures Health Canada License for FreeStyle® Libre System for People with Diabetes

Abbott today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes. The first-of-its-kind system eliminates the need for routine finger sticks,1 requires...

Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care

March 19, 2017 Late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. The CardioMEMS HF...